Karyopharm Therapeutics Inc (KPTI) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $9.35
• Market Cap: $185.09M
• EPS: $-17.93
• 52-Week High: $10.99
• 52-Week Low: $3.51

Market Sentiment

Karyopharm Therapeutics Inc currently has a Bullish sentiment score of 0.22.

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a biopharmaceutical innovator headquartered in Newton, Massachusetts, specializing in the development of therapies that target nuclear export and key oncological pathways. Leveraging its proprietary SINE™ (Selective Inhibitor of Nuclear Export) technology platform, the company aims to address significant unmet medical needs in cancer care. Karyopharm's lead product, Xpovio (selinexor), has received multiple regulatory approvals, underscoring its commitment to i...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Karyopharm Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does KPTI pay dividends?

Karyopharm Therapeutics Inc (KPTI) does not currently pay a regular dividend.

What is KPTI's market cap?

Karyopharm Therapeutics Inc (KPTI) has a market capitalization of $185.09M with a current stock price of $9.35.